Evidence map›Paper›PMID 31980982›Full record

ArticleClinical and experimental medicine2020

Gene expression profiling revealed MCM3 to be a better marker than Ki67 in prognosis of invasive ductal breast carcinoma patients.

Yue Zhao, Yimin Wang, Fudi Zhu, Jiayu Zhang, Xiao Ma, Dongwei Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  7. Concurrent RB1 loss andmedRxiv : the preprint server for health sciences · 2023
    Article
  8. Review
  9. Article
  10. Article
  11. Systematic analysis of MCM3 in pediatric medulloblastomaFrontiers in molecular biosciences · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yue ZhaoDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Yimin WangDepartment of Surgery, Harbin Medical University, Harbin, China.
Fudi ZhuDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Jiayu ZhangDepartment of Surgery, the Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin, 150086, Heilongjiang, China.
Xiao MaDepartment of Surgery, Jinan Maternal and Child Health Care Hospital, 2 Jianguo Xiaojing Third Road, Jinan, 250000, Shandong, China. wei514344440@126.com.
Dongwei ZhangDepartment of Surgery, the Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin, 150086, Heilongjiang, China. 15245063700@163.com.ORCID http://orcid.org/0000-0002-0983-8542
Harbin Medical University · CNJinan Maternity And Care Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invasive ductal carcinoma (IDC) is the most common breast cancer. Our study used gene microarray data to select differentially expressed genes between normal and IDC mammary tissues. From these, we selected genes related to the proliferation of tumor cells and compared their prognostic value with known biomarker Ki67 for IDC. Analysis of publicly available Gene Expression Omnibus (GEO) data revealed 24 differentially expressed genes (DEGs) in normal and 31 DEGS in IDC tissues that were used for further analyses. Gene chip analysis software was used to identify DEGs. DEG profiles were confirmed using quantitative PCR (qPCR). DEG functions where shown to be related to cell proliferation. We confirmed MCM3 expression using immunohistochemical staining in 45 IDC patients. The relationship between MCM3 expression and survival was investigated using Kaplan-Meier survival curves and Cox proportional hazard regression models. A total of 1307 differentially expressed genes were identified between IDC and normal tissues, which were enriched in 32 Gene Ontology (GO) terms and 9 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. qPCR demonstrated that both COL1A1 and MCM3 were significantly up-regulated in IDC tissues, of which only MCM3 was related to cell proliferation. Ki67 is closely associated with the tumor grade, ER status, PR status and HER2 status, while MCM3 was shown to relate to tumor size, lymph node, and PR status. There was significant association between survival and MCM3, but not for Ki67. High MCM3 expression demonstrated statistically significant associations with poor prognosis in IDC patients. Findings from the gene microarray data analysis confirmed that MCM3 is associated with the response to cell proliferation. MCM3 represents a better proliferation marker than Ki67 making it a valuable prognostic tool that is independent of ER and HER2 status.

Indexed as

AdultAgedBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansKaplan-Meier EstimateKi-67 AntigenMiddle AgedMinichromosome Maintenance Complex Component 3Oligonucleotide Array Sequence AnalysisPrognosisBiomarkers, TumorKi-67 AntigenMCM3 protein, humanMinichromosome Maintenance Complex Component 3MKI67 protein, humanCell proliferationGene microarray dataInvasive ductal carcinomaKi67MCM3

Identifiers

PMID31980982
OpenAlexW3001825118

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.